BYNDER
Bynder, a global leader in enterprise digital asset management (DAM), has revealed how the accelerated adoption of the company’s AI-powered solutions and strategic DAM deployments have driven record growth in the first half of 2024.
More than 350 customers have adopted Bynder’s enhanced AI Search Experience since its launch nine months ago, and through the solution, more than 30 million images have been processed. Bynder, which currently has over 150 million active assets on its platform, also reported that in the first half of the year, it has seen a 20% year-on-year increase in the delivery of assets to connected systems. With assets delivered 113 billion times in the first half of the year, this shows that Bynder’s customers are continuing to leverage content as a strategic differentiator to deliver exceptional content experiences.
Bynder first integrated AI into its platform in 2016, demonstrating the company’s long-term commitment well before it became mainstream. Since then, Bynder has accelerated its efforts by acquiring an AI company and launching AI Search Experience, continually enhancing its AI capabilities and giving customers governance and control over how AI is used in their organizations and on their own terms.
Since the launch of Bynder’s AI Search Experience, many of Bynder's customers have adopted the solution, reinforcing the trend that AI is increasingly viewed as a strategic tool for marketers seeking to streamline content operations and improve customer experience. This trend validates Bynder's approach to AI, demonstrating the need to harness AI responsibly to deliver tangible benefits to its customers.
Bynder’s AI-powered DAM platform is pivotal in supporting go-to-market operations and the adoption of AI within content operations has driven the rapid uptake of Bynder’s AI Search Experience. This solution is customer-inspired and enables teams to maximize asset reuse, save resources, reduce time spent searching for assets, and automatically eliminate duplicates.
The benefits of the solution were evidenced at Bynder’s recent customer Spotlight Awards where brands such as Viator, Les Mills and Inspire Brands were recognized for their excellence in innovation, creating compelling value and return on investment when it comes to the implementation and use of Bynder DAM.
By leveraging AI-powered recommendations and filtering options, Inspire Brands was able to quickly locate and distribute relevant assets across its portfolio of sub-brands. This new level of findability has promoted content reuse within the organization and increased the value of the assets that the company invests in.
Cliff Crosbie, Head of AI Strategies at Bynder, said: “It’s great to see that our ongoing innovation and market leadership in AI has continued to drive growth in the first half of this year, along with our strategic DAM deployments which have both become invaluable solutions for our customers. The digital landscape continues to evolve faster than ever, so it’s our aim to implement AI responsibly to help drive scale and efficiency and we’re looking forward to bringing the next phase of our AI enhancements to market very soon.”
As a result of the company’s accelerated growth, Bynder has appointed Ann-Michèle Verheyden as its new Chief Legal Officer. Ann-Michèle brings extensive experience in SaaS, IP and privacy, supporting Bynder’s position and investment in AI where she will be building a robust compliance framework enabling businesses to navigate the complexities of AI-driven technology while mitigating risk.
Richard Heitmann also joins Bynder as its new Chief Marketing Officer. Richard brings a wealth of experience from high-growth startups like Aspera and enterprise software experience from IBM. Richard’s expertise will help drive further growth and bring Bynder’s platform innovations to the market.
Looking forward to the second half of the year, Bynder will host its inaugural customer event, Bynder Connect, in September in Amsterdam. The event will bring together industry leaders to share insights, launch new innovations, and celebrate successes with its customers.
For more information on Bynder’s AI-powered DAM, please visit: https://www.bynder.com/en/solutions/initiatives/ai-automation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724434819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom